Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
imdusiran
- Development stage
- Phase 2
- Lead developer
- Arbutus Biopharma
- Modality
- Gene Therapies, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Administration
- Subcutaneous
01
Overview
Imdusiran is a second-generation, N-acetylgalactosamine (GalNAc) conjugated small interfering RNA (siRNA) therapeutic developed for the treatment of chronic hepatitis B virus (HBV) infection. It is specifically designed to reduce all HBV viral proteins and antigens, including hepatitis B surface antigen (HBsAg), which is considered a key prerequisite for reawakening the patient’s immune response against the virus. Imdusiran targets hepatocytes using GalNAc delivery technology, enabling subcutaneous administration. Preclinical and clinical data have shown that imdusiran effectively reduces HBsAg levels, viral antigens, and HBV DNA in patients with chronic hepatitis B. The drug has demonstrated pan-genotypic activity and retains efficacy against resistant HBV isolates. Imdusiran acts through direct RNA interference without stimulating cytokine release or causing significant adverse events in trials to date[1][3][5][6].
- Other names
- imdusiran
02
Targets
ASGPR (Asialoglycoprotein Receptor 1)HBV RNA (Hepatitis B virus RNA)HBsAg (Hepatitis B surface antigen)HBV (Hepatitis B virus)
Beyond the preview
Go deeper on imdusiran.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on imdusiran.